Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?

Supplementary Protection Certificates & their potential impact on availability of biosimilars

Date

21 Oct 2018

Session

ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?

Presenters

Roberto Romandini

Authors

R. Romandini

Author affiliations

-, Max Planck Institute of Immunobiology and Epigenetics, DE-79108 - Freiburg im Breisgau/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

21 Oct 2018

ESMO COLLOQUIUM - Are biosimilars the key to access, in practice? - Introduction

Presenter: E.G. Elisabeth de Vries

Session: ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?

Resources:

Slides

Webcast

21 Oct 2018

Acceptance of oncology biosimilars in supportive care: a success story

Presenter: Martina Weiss

Session: ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?

Resources:

Slides

Webcast

21 Oct 2018

Existing challenges for uptake of oncology biosimilars – ESMO survey results

Presenter: Malvika Vyas

Session: ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?

Resources:

Slides

Webcast

21 Oct 2018

In practice (UK): patients being switched from a biologic to a biosimilar - UK

Presenter: Stephen Scowcroft

Session: ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?

Resources:

Slides

Webcast

21 Oct 2018

One year on – state of play in the EU on oncology biosimilars

Presenter: Murray Aitken

Session: ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?

Resources:

Slides

Webcast